The therapeutic efficacy of sulfadoxine/pyrimethamine against Plasmodium falciparum in Yemen

Medical Principles and Practice

Volumn 18, Issue 1, 2008, Pages 62-66

  Al Kabsi, Abdulgodos M ^a   Al Shamahy, Hassan A ^a   Al Harazy, Abdulilah Hussein ^a   Harmal, Nabil S ^a  

^a SANA A UNIVERSITY   (Yemen)

Author keywords

Drug resistant malaria; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Therapeutic efficacy; Yemen

Indexed keywords

FANSIDAR;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YEMEN;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MICROBIAL SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SCHIZONTS; SEX DISTRIBUTION; SULFADOXINE; YEMEN; YOUNG ADULT;

EID: 57349112340     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163049     Document Type: Article

References (24)

1. World Health Organization: Guidelines for the treatment of malaria (WHO/HTM/MAL/2006.1108). 2006. http://www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf.
2. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR: Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-218.
3. World Health Organization: World malaria report 2005 (WHO/HTM/MAL/2005. 1102). 2005, annex 1.205. http://www.rbm.who.int/wmr2005/html/toc.htm.
4. Bloland PB: Drug resistance in malaria. 2001. http://www.who.int/csr/ resources/publications/drugresist/malaria.pdf.
5. Wernsdorfer WH: Epidemiology of drug resistance in malaria. Acta Trop 1994;56:143-156.
6. Linares GE, Rodriguez JB: Current status and progresses made in malaria chemotherapy. Curr Med Chem 2007;14:289-314.
7. Abdel-Hameed AA: Antimalarial drug resistance in the eastern Mediterranean region. East Mediterr Health J 2003;9:492-508.
8. Thimasarn K, Pinichpongse S, Malikul S, Rooney W, Tansophalaks S: Phase III double-blind comparative study of Fansimef and Lariam for the curative treatment of Plasmodium falciparum infections in Thailand. Southeast Asian J Trop Med Public Health 1990;21:404-411.
9. Talisuna AOP, Langi P, Bakyaita N, Egwang T, Mutabingwa TK, Watkins W, Van Marck E, D'Alessandro U: Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? Trans R Soc Trop Med Hyg 2002;96:310-317.
10. Ibrahm ML, Gay-Andrieu F, Adehossi E, Lacroix V, Randrianarivelojosia M, Duchemin JB: Field-based evidence for the linkage of pfcrt and pfdhfr drug-resistant malaria genotypes and clinical profiles of severe malaria in Niger. Microbes Infect 2007;9:599-604.
11. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). 2003. http://www.who.int/malaria/docs/ProtocolWHO.pdf.
12. Yemeni Ministry of Public Health and Population. National Malaria Control Program. Annual report. 2002;2:1-20.
13. Alharazi A, Al-Shamahy HA, Al-Kabsi A, Harmal N: The Prevalence and Degree of Resistance of P. falciparum to First-Line Drugs: An In Vitro Study of P. falciparum from an Endemic Region in Yemen; thesis, Sana'a University, 2004, p 101.
14. World Health Organization. In vitro microtest (Mark III) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, amodiaquine, sulfadoxine/pyrimethamine and artemisinin (CTD/MAL/97.20). 2001. http://www.who.int/drugresistance/malaria/en/markiii.pdf.
15. Werrell DA, Watkins WM, Winstanley PA: Treatment and prevention of malaria; in Gilles HM, Warrell DA (eds): Essential Malariology, ed 4. London, Arnold, 2002, pp 282-303.
16. Ministry of Public Health and Population: National Malaria Control Program. 3rd National Seminar on Malaria and Other Vector Borne Diseases, Sana'a, 20-22 November 2005.
17. World Health Organization: Improving access to antimalarial medicines: report of the RBM Partnership meeting, 30 September-2 October 2002. 2003. http://www.who.int/malaria/cmc_upload/0/000/016/746/2002-sept_meeting.pdf.
18. Newman RD, Moran AC, Kayentao K, Benga-De E, Yameogo M, Gaye O, Faye O, Lo Y: Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action. Trop Med Int Health 2006;11:462-469.
19. Gatton ML, Martin LB, Cheng Q: Evolution of resistance to sulfadoxine/pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother 2004;48:2116-2123.
20. Khalil I, Alifrangis M, Ronn AM, Gabar HA, Jelinek T, Sctti GM, Bygbijerg JC: Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. Am J Trop Med Hyg 2002;67:225-229.
21. Mehta SR, Das S: Management of malaria: recent trends. J Commun Dis 2006;38:130-138.
22. World Health Organization: Report on the responsiveness of the RBM Programme to country needs in the WHO Eastern Mediterranean region (WHO-EM/MAL/307/E). 2004. http://www.emro.who.int/dsaf/dsa524.pdf.
23. Ringwald P: Monitoring antimalarial drug efficacy. Clin Infect Dis 2004;38:1192-1193.
24. Attlmayr B, Thriemer K, Haque R, Wagatsuma Y, Abdus Salam M, Akhter S, Fukuda M, Schaecher K, Miller RS, Noedl H: In vitro antimalarial drug resistance in Southeastern Bangladesh. Wien Klin Wochenschr 2006;118:58-61.